No abstract

ObjectiveTo investigate relapse rates after the successful treatment of patients with non‐atypical endometrial hyperplasia who were randomised to either a levonorgestrel‐impregnated intrauterine system (LNG‐IUS; Mirena®) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response.DesignA multicentre randomised trial.SettingTen different outpatient clinics localised in hospitals and seven gynaecological private practices in Norway.PopulationOne hundred and fifty‐three women aged 30–70 years with low‐ or medium‐risk endometrial hyperplasia met the inclusion criteria, and 153 completed the therapy.MethodsPatients were randomly assigned to one of the following three treatment arms: LNG‐IUS; 10 mg of oral MPA administered for 10 days per cycle for 6 months; or 10 mg of oral MPA administered daily for 6 months. The women were followed for 24 months after ending therapy.Main outcome measuresHistological relapse of endometrial hyperplasia.ResultsHistological relapse was observed in 55/135 (41%) women who had an initial complete treatment response. The relapse rates were similar in the three therapy groups (P = 0.66). In the multivariable analyses relapse was dependent on menopausal status (P = 0.0005) and estrogen level (P = 0.0007).ConclusionsThe risk of histological relapse of non‐atypical endometrial hyperplasia is high within 24 months of ceasing therapy with either the LNG‐IUS or oral MPA. Continued endometrial surveillance and prolonging progestogen therapy should be considered.Tweetable abstractRelapse of endometrial hyperplasia after successful treatment is independent of therapy regime.